Goldman Sachs

The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.

The investment bank expressed doubts about Qiagen's GeneReader NGS platform, among other things, and Bruker's mixed recent record on improving its operations.

NEW YORK (GenomeWeb) – Investment banks Goldman Sachs and Leerink Partners initiated coverage of T2 Biosystems today with a Neutral and Market Perform rating, respectively, on the firm's stock.

NEW YORK (GenomeWeb) – Goldman Sachs today reinstated a Neutral rating for Agilent Technologies with a 12-month price target on the company's shares of $58.

NEW YORK (GenomeWeb News) – Goldman Sachs today downgraded Agilent Technologies and Genomic Health, but upgraded Waters.

NEW YORK (GenomeWeb News) – Quest Diagnostics has entered into an agreement with Goldman Sachs to repurchase about $450 million of its stock, the company said in a document filed with the US Securities and Exchange Commission today.

NEW YORK (GenomeWeb News) – Investment bank Goldman Sachs today upgraded shares of Quest Diagnostics and Laboratory Corporation of America, but downgraded Sigma-Aldrich.

NEW YORK (GenomeWeb News) – T2 Biosystems today announced the completion of $40 million in financing to support its clinical programs and commercialization of its molecular diagnostic panel for the identification of species-specific Candida fungal infections.

NEW YORK (GenomeWeb News) – Despite a temporary deal in Washington to avert the fiscal cliff, spending by academic research laboratories on life science research tools may remain flat in the short to medium term, according to survey results released today by Goldman Sachs.

NEW YORK (GenomeWeb News) – Goldman Sachs today resumed coverage of Danaher with a Neutral rating and a 12-month price target of $57.

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.